ADME (absorption, distribution, metabolism, excretion): The real meaning-avoiding disaster and maintaining efficacy for preclinical candidates

Katherine Tsaioun, Steven A. Kates

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The purpose of preclinical Absorption, Distribution, Metabolism, Excretion, and Toxicity also referred to as early drug metabolism and pharmacokinetics is to reduce the risk of drug development to avoid spending scarce resources on weak lead candidates and expensive R&D programs and clinical trials. This allows drug-development resources to be focused on fewer, but more-likely-to-succeed drug candidates. This chapter provides the rationale for effective preclinical drug development using a systematic approach to limit failure.

Original languageEnglish (US)
Title of host publicationTranslational Stroke Research
Subtitle of host publicationFrom Target Selection to Clinical Trials
PublisherSpringer New York
Pages617-638
Number of pages22
ISBN (Electronic)9781441995308
ISBN (Print)9781441995292
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Disasters
Pharmaceutical Preparations
Pharmacokinetics
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Tsaioun, K., & Kates, S. A. (2012). ADME (absorption, distribution, metabolism, excretion): The real meaning-avoiding disaster and maintaining efficacy for preclinical candidates. In Translational Stroke Research: From Target Selection to Clinical Trials (pp. 617-638). Springer New York. https://doi.org/10.1007/978-1-4419-9530-8_30

ADME (absorption, distribution, metabolism, excretion) : The real meaning-avoiding disaster and maintaining efficacy for preclinical candidates. / Tsaioun, Katherine; Kates, Steven A.

Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, 2012. p. 617-638.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tsaioun, Katherine ; Kates, Steven A. / ADME (absorption, distribution, metabolism, excretion) : The real meaning-avoiding disaster and maintaining efficacy for preclinical candidates. Translational Stroke Research: From Target Selection to Clinical Trials. Springer New York, 2012. pp. 617-638
@inbook{5ecde4da1ec34f398105ff4f757a5880,
title = "ADME (absorption, distribution, metabolism, excretion): The real meaning-avoiding disaster and maintaining efficacy for preclinical candidates",
abstract = "The purpose of preclinical Absorption, Distribution, Metabolism, Excretion, and Toxicity also referred to as early drug metabolism and pharmacokinetics is to reduce the risk of drug development to avoid spending scarce resources on weak lead candidates and expensive R&D programs and clinical trials. This allows drug-development resources to be focused on fewer, but more-likely-to-succeed drug candidates. This chapter provides the rationale for effective preclinical drug development using a systematic approach to limit failure.",
author = "Katherine Tsaioun and Kates, {Steven A.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-9530-8_30",
language = "English (US)",
isbn = "9781441995292",
pages = "617--638",
booktitle = "Translational Stroke Research",
publisher = "Springer New York",

}

TY - CHAP

T1 - ADME (absorption, distribution, metabolism, excretion)

T2 - The real meaning-avoiding disaster and maintaining efficacy for preclinical candidates

AU - Tsaioun, Katherine

AU - Kates, Steven A.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The purpose of preclinical Absorption, Distribution, Metabolism, Excretion, and Toxicity also referred to as early drug metabolism and pharmacokinetics is to reduce the risk of drug development to avoid spending scarce resources on weak lead candidates and expensive R&D programs and clinical trials. This allows drug-development resources to be focused on fewer, but more-likely-to-succeed drug candidates. This chapter provides the rationale for effective preclinical drug development using a systematic approach to limit failure.

AB - The purpose of preclinical Absorption, Distribution, Metabolism, Excretion, and Toxicity also referred to as early drug metabolism and pharmacokinetics is to reduce the risk of drug development to avoid spending scarce resources on weak lead candidates and expensive R&D programs and clinical trials. This allows drug-development resources to be focused on fewer, but more-likely-to-succeed drug candidates. This chapter provides the rationale for effective preclinical drug development using a systematic approach to limit failure.

UR - http://www.scopus.com/inward/record.url?scp=84990232094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990232094&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-9530-8_30

DO - 10.1007/978-1-4419-9530-8_30

M3 - Chapter

AN - SCOPUS:84990232094

SN - 9781441995292

SP - 617

EP - 638

BT - Translational Stroke Research

PB - Springer New York

ER -